Epic Trust Investment Advisors LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 5.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,211 shares of the medical research company’s stock after selling 70 shares during the quarter. Epic Trust Investment Advisors LLC’s holdings in Amgen were worth $349,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the stock. International Assets Investment Management LLC purchased a new position in shares of Amgen during the 4th quarter worth $4,589,900,000. Assenagon Asset Management S.A. increased its stake in shares of Amgen by 486.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 899,232 shares of the medical research company’s stock valued at $258,997,000 after acquiring an additional 745,929 shares during the last quarter. abrdn plc lifted its holdings in shares of Amgen by 150.4% during the 4th quarter. abrdn plc now owns 1,043,609 shares of the medical research company’s stock worth $300,580,000 after acquiring an additional 626,810 shares during the period. Royal Bank of Canada grew its holdings in Amgen by 11.4% in the third quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company’s stock valued at $1,365,213,000 after purchasing an additional 518,689 shares during the period. Finally, California Public Employees Retirement System increased its position in Amgen by 22.0% during the fourth quarter. California Public Employees Retirement System now owns 2,716,088 shares of the medical research company’s stock worth $782,288,000 after purchasing an additional 490,539 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Amgen Price Performance
Shares of AMGN stock traded down $2.44 during midday trading on Tuesday, reaching $273.94. 1,474,546 shares of the company were exchanged, compared to its average volume of 2,799,766. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72. The company has a market cap of $146.94 billion, a P/E ratio of 22.04, a PEG ratio of 2.61 and a beta of 0.58. The company’s 50 day moving average price is $274.96 and its two-hundred day moving average price is $281.45. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65.
Amgen Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.29%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is 72.06%.
Wall Street Analyst Weigh In
AMGN has been the subject of several research reports. TD Cowen lowered their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Raymond James initiated coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating for the company. UBS Group cut their price target on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $329.00 target price on shares of Amgen in a research report on Wednesday, April 3rd. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $297.40.
Read Our Latest Research Report on AMGN
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What is a Death Cross in Stocks?
- Hilton Demonstrates Asset Light is Right for Investors
- Dividend Capture Strategy: What You Need to Know
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.